Nothing Special   »   [go: up one dir, main page]

PE20221409A1 - Anticuerpos anti-cd73 y usos de estos - Google Patents

Anticuerpos anti-cd73 y usos de estos

Info

Publication number
PE20221409A1
PE20221409A1 PE2022001337A PE2022001337A PE20221409A1 PE 20221409 A1 PE20221409 A1 PE 20221409A1 PE 2022001337 A PE2022001337 A PE 2022001337A PE 2022001337 A PE2022001337 A PE 2022001337A PE 20221409 A1 PE20221409 A1 PE 20221409A1
Authority
PE
Peru
Prior art keywords
antibodies
vectors
cells
disclosed
methods
Prior art date
Application number
PE2022001337A
Other languages
English (en)
Inventor
Horacio G Nastri
Shaun M Stewart
Juan Carlos Almagro
Jing Zhou
Rebecca A Buonpane
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20221409A1 publication Critical patent/PE20221409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos anti-CD73. Tambien se describen acidos nucleicos, vectores, celulas y composiciones farmaceuticas relacionados. Tambien se describen metodos para tratar el cancer con los anticuerpos anti-CD73.
PE2022001337A 2020-01-03 2020-12-30 Anticuerpos anti-cd73 y usos de estos PE20221409A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062956847P 2020-01-03 2020-01-03
PCT/US2020/067533 WO2021138467A1 (en) 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20221409A1 true PE20221409A1 (es) 2022-09-20

Family

ID=74347717

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001337A PE20221409A1 (es) 2020-01-03 2020-12-30 Anticuerpos anti-cd73 y usos de estos

Country Status (18)

Country Link
US (2) US12018089B2 (es)
EP (1) EP4084825A1 (es)
JP (1) JP2023509448A (es)
KR (1) KR20220121850A (es)
CN (1) CN115135341A (es)
AR (1) AR120936A1 (es)
AU (1) AU2020417804A1 (es)
BR (1) BR112022013236A2 (es)
CA (1) CA3166533A1 (es)
CL (1) CL2022001769A1 (es)
CO (1) CO2022009248A2 (es)
CR (1) CR20220317A (es)
EC (1) ECSP22051701A (es)
IL (1) IL294436A (es)
MX (1) MX2022007575A (es)
PE (1) PE20221409A1 (es)
TW (1) TW202128768A (es)
WO (1) WO2021138467A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
MA53097A (fr) 2018-07-05 2021-05-12 Incyte Corp Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
IL294437A (en) 2020-01-03 2022-09-01 Incyte Corp Combination therapy cd73 and a2a/a2b adenosine receptor inhibitors
KR20220121850A (ko) 2020-01-03 2022-09-01 인사이트 코포레이션 항-cd73 항체 및 이의 용도
KR20230157940A (ko) * 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
JP2024537188A (ja) * 2021-10-08 2024-10-10 アーベル リミテッド カドヘリン－１７タンパク質を検出するための組成物及び方法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1642596A3 (en) 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
EP1286692A4 (en) 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US20040202658A1 (en) 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
BRPI0612947A2 (pt) 2005-05-18 2010-12-07 Biogen Idec Inc método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
ES2821964T3 (es) 2014-10-10 2021-04-28 Innate Pharma Bloqueo de CD73
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
CN107001472B (zh) 2014-11-10 2020-12-11 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
BR112018067368A2 (pt) * 2016-03-04 2019-01-15 Bristol-Myers Squibb Company terapia de combinação com anticorpos anti-cd73
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
KR20190091281A (ko) 2016-12-13 2019-08-05 아스텔라스세이야쿠 가부시키가이샤 항인간 cd73 항체
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
EA202090104A1 (ru) 2017-06-22 2020-04-09 Новартис Аг Молекулы антител к cd73 и пути их применения
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3762421A2 (en) * 2018-03-09 2021-01-13 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
BR112020016049A2 (pt) 2018-03-09 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anti-cd73 e seus usos
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
CN112218657A (zh) 2018-04-12 2021-01-12 百时美施贵宝公司 Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
MA53097A (fr) 2018-07-05 2021-05-12 Incyte Corp Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
CA3118706A1 (en) 2018-11-05 2020-05-14 Corvus Pharmaceuticals, Inc. B-cell activating cd73 antibodies
US20220220218A1 (en) 2018-11-12 2022-07-14 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
TWI790445B (zh) 2019-06-06 2023-01-21 大陸商北京加科思新藥研發有限公司 對cd73具有特異性的結合分子及其用途
CN117946274A (zh) 2019-06-19 2024-04-30 海正生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3999545A4 (en) 2019-08-21 2023-09-13 Harbour Biomed (Shanghai) Co., Ltd ANTI-CD73 ANTIBODIES AND USE THEREOF
CR20220124A (es) 2019-08-26 2022-06-15 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b
CN115023439A (zh) 2019-09-06 2022-09-06 西福根有限公司 抗cd73抗体
EP4051713A4 (en) 2019-11-01 2024-05-01 Corvus Pharmaceuticals, Inc. ANTI-CD73 IMMUNOMODULATING ANTIBODIES AND THEIR USES
US20220403041A1 (en) 2019-11-15 2022-12-22 Genzyme Corporation Biparatopic cd73 antibodies
JP2023510113A (ja) 2019-12-19 2023-03-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽腫を処置するための方法
KR20220121850A (ko) 2020-01-03 2022-09-01 인사이트 코포레이션 항-cd73 항체 및 이의 용도
IL294437A (en) 2020-01-03 2022-09-01 Incyte Corp Combination therapy cd73 and a2a/a2b adenosine receptor inhibitors
JP2023521362A (ja) 2020-04-09 2023-05-24 エイプリルバイオ カンパニー リミテッド Ｃｄ７３免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用
IL297426A (en) 2020-04-22 2022-12-01 Akeso Biopharma Inc Anti-cd73 antibody and its use
AU2020447878A1 (en) 2020-05-12 2023-02-02 Biotheus Inc. Anti-CD73 antibody and use thereof
JPWO2021241729A1 (es) 2020-05-29 2021-12-02
JP2023532234A (ja) 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
KR20230157940A (ko) 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법

Also Published As

Publication number Publication date
MX2022007575A (es) 2022-09-23
CO2022009248A2 (es) 2022-08-19
JP2023509448A (ja) 2023-03-08
CA3166533A1 (en) 2021-07-08
TW202128768A (zh) 2021-08-01
US20240352143A1 (en) 2024-10-24
IL294436A (en) 2022-09-01
AR120936A1 (es) 2022-03-30
CR20220317A (es) 2022-09-02
US12018089B2 (en) 2024-06-25
KR20220121850A (ko) 2022-09-01
AU2020417804A1 (en) 2022-07-21
EP4084825A1 (en) 2022-11-09
WO2021138467A1 (en) 2021-07-08
US20210230293A1 (en) 2021-07-29
ECSP22051701A (es) 2022-08-31
CL2022001769A1 (es) 2023-01-20
CN115135341A (zh) 2022-09-30
BR112022013236A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
CL2022001769A1 (es) Anticuerpos anti-cd73 y usos de estos.
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
AR115389A1 (es) Anticuerpo antagonista de cd73
AR114275A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
PE20210110A1 (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112022005114A2 (pt) Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
BR112021019701A2 (pt) Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
DOP2024000036A (es) Anticuerpos anti-psma y usos de estos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
CO2021005083A2 (es) Distrofinas miniaturizadas y usos de las mismas
CO2024009042A2 (es) Anticuerpos anti-calreticulina (calr) mutante y usos de estos
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
UY39699A (es) Anticuerpos anti-tau y usos de estos
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
CO2021007444A2 (es) Anticuerpos antiperiostina y usos de estos
CO2023010689A2 (es) Anticuerpos y usos de estos
MX2020012788A (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso.